About Us
 

The Company

Diabetology is a specialty biopharmaceutical company employing a proprietary oral delivery system to administer known bioactives as well as novel compounds for the comprehensive management of diabetes.

Our philosophy is to form collaborations & partnerships to further key projects, and to outsource many non-core activities. Thus we are able to keep overheads low, conserving shareholders' resources.

Based in Jersey, Diabetology is a privately owned and funded company with a research and business development activity in London UK and Karlsruhe Germany.

Orally Delivered Drugs
Advancing Therapies for Diabetes

Key Projects

Capsulin™ OAD (oral anti-diabetic)

Primary Indication Treatment of Type 2 diabetes mellitus
Stage of Development Phase II
  • Diabetology has identified classes of compounds that appear to facilitate insulin absorption in the small intestine adequately to meet clinical and commercial objectives, and that are already used for completely different purposes as excipients in pharmaceutical formulations
  • Use of such agents in its third-generation Axcess™ delivery technology thereby obviates one major aspect of regulatory risk - the risk of toxicity with novel facilitator agents or carriers - while also potentially reducing development timelines by eliminating the need for certain preparatory toxicology studies
  • Use of such agents for oral peptide delivery is novel and, the Company believes, patentable; the Company has exclusive licenses in the field of diabetes to a series of patent applications covering Axcess delivery technology
  • Potentially improving glycaemic control through optimal physiological delivery route
  • Also, potentially improving compliance
  • Finally, the Company believes that its readily available facilitator compounds may endow it with advantages over competing oral insulin delivery systems that seek to employ new chemical entities

Capsulin™ IR (insulin replacement)

Primary Indication Treatment of Type 1 diabetes mellitus
Stage of Development Phase II
  • As an alternative to inhaled/injected insulin, Capsulin™ IR will effectively deliver insulin orally to those with Type 1 diabetes and late stage Type 2, where they are dependent on insulin supplementation
  • Reducing the need for injections and/or inhaler equipment
  • Potentially improving glycaemic control through optimal physiological delivery route
  • Improving compliance

Oral GLP-1 Analogue

Primary Indication Treatment of Type 2 diabetes mellitus
Stage of Development Preclinical
  • Outlicensing opportunity - providing oral formulation technology to GLP-1 analogue
  • Stimulates insulin formation and release when blood glucose levels are high
  • Reduces glucose output from the liver
  • Improves insulin sensitivity and the function of ß-cells
  • Slows emptying of stomach and reduces desire to eat

Combulin™

Primary Indication Treatment of Type 2 diabetes mellitus
Stage of Development Preclinical
  • As a follow-on product to Capsulin, Diabteology is developing an oral combination therapy bringing insulin and insulin sensitizing agents together
  • Therapeutic benefit from simultaneous dosing of insulin and insulin sensitizer